Upstart UPST 深 滬
已收盤 08-01 16:00:00 美东时间
79.22
-2.520
-3.08%
華盛通- 最 高82.358
- 今 開78.023
- 成交量 683.82万股
- 最 低 76.08
- 昨 收 81.74
- 總市值 75.37亿
- 52周最高 96.4294
- 市盈率 靜 --
- 換手率 7.19%
- 52周最低 31.40
- 委 比 55.11%
- 總股本 9514.49万
- 歷史最高 401.49
- 量 比 1.28
- 振 幅 7.68%
- 歷史最低 11.93
- 每 手 1
- 風險率 7.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多散户抱团概念股指数/迷因股（meme stock）指数跌0.37%
散户抱团概念股指数/迷因股（meme stock）指数跌0.37%，报13.53点。经历了连续四个交易日的大起大落、连续三个交易日重挫之后，跌幅有所放缓。个股...
07-31 05:27
今年最大的科技IPO来了！设计软件巨头Figma上市在即，AI软件股能否借势腾飞？
投资者疯抢！Figma IPO认购火爆，将于7月31日（周四）正式登陆纽交所。作为硅谷炙手可热的设计软件独角兽，Figma成色几何？>>
07-30 17:56
Upstart Holdings: AI Model Sparks Stock Surge
Upstart Holdings ( ($UPST) ) has risen by 8.93%. Read on to learn why. Upstart ...
07-26 22:03
Opendoor stock adds to meteoric rise amid retail frenzy
Opendoor Technologies (NASDAQ:OPEN) shares extended its multi-day surge in Monday morning trading, in a move driven by speculative retail traders. The real estate platform's stock accelerated 52% at 1...
07-21 22:45
期权扫描 | 乐道L90正式开启预售！蔚来看涨期权占比近76%；SBET期权成交近15万张
乐道L90正式开启预售！蔚来期权成交量达42万张，看涨期权占比近76%；SBET稳居以太坊第一大持仓机构，隔夜期权成交近15万张>>
07-15 19:15
10 Financials Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
07-15 01:36
期权扫描 | 英伟达期权成交量达292万张；西南航空获一CALL押注看涨至35.5美元
英伟达市值一度突破4万亿美元！期权成交量达292万张；获大行上调目标价，西南航空一CALL押注看涨至35.5美元；Coinbase看涨期权成交占比超70%>>
07-10 19:24
Tradr Prepares Five Leveraged Single-Stock ETF Launches
First-to-market ETFs on CoreWeave, AST SpaceMobile, Constellation Energy, GE Vernova & NuScale Power NEW YORK, July 9, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophis...
07-10 01:11
美股异动 | Wolfspeed月内暴涨700%！部分AI应用股飙涨
Wolfspeed盘初涨超40%，股价月内暴涨700%！部分AI应用股飙涨，SoundHound AI大涨15%，BBAI涨超9%>>
07-08 21:55
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Upstream Bio, Inc. has initiated a Phase 2 clinical trial, VENTURE (NCT06981078), evaluating verekitug, a TSLP receptor antagonist, in patients with moderate-to-severe COPD. The trial will assess its efficacy and safety when administered every 12 or 24 weeks. Verekitug is the only known biologic targeting the TSLP receptor, with potential benefits for COPD treatment. The primary endpoint is the annualized rate of moderate or severe COPD exacerbat...
07-08 11:00
